A multidisciplinary consensus on the morphological and functional responses to immunotherapy treatment
Clin. transl. oncol. (Print)
; 23(3): 434-449, mar. 2021. ilus
Artículo
en Inglés
| IBECS
| ID: ibc-220879
Biblioteca responsable:
ES1.1
Ubicación: ES15.1 - BNCS
ABSTRACT
The implementation of immunotherapy has radically changed the treatment of oncological patients. Currently, immunotherapy is indicated in the treatment of patients with head and neck tumors, melanoma, lung cancer, bladder tumors, colon cancer, cervical cancer, breast cancer, Merkel cell carcinoma, liver cancer, leukemia and lymphomas. However, its efficacy is restricted to a limited number of cases. The challenge is, therefore, to identify which subset of patients would benefit from immunotherapy. To this end, the establishment of immunotherapy response criteria and predictive and prognostic biomarkers is of paramount interest. In this report, a group of experts of the Spanish Society of Medical Oncology (SEOM), the Spanish Society of Medical Radiology (SERAM), and Spanish Society of Nuclear Medicine and Molecular Imaging (SEMNIM) provide an up-to-date review and a consensus guide on these issues (AU)
Texto completo:
Disponible
Colección:
Bases de datos nacionales
/
España
Base de datos:
IBECS
Asunto principal:
Antineoplásicos Inmunológicos
/
Neoplasias
Límite:
Humanos
País/Región como asunto:
Europa
Idioma:
Inglés
Revista:
Clin. transl. oncol. (Print)
Año:
2021
Tipo del documento:
Artículo
Institución/País de afiliación:
Bellvitge University Hospital IDIBELL/Spain
/
Centro Integral Oncologico HM Clara Campal/Spain
/
Clinica Universidad de Navarra/Spain
/
Hospital Clínic/Spain
/
Hospital Clínico Universitario de Santiago de Compostela/Spain
/
Hospital Universitari Vall Hebron/Spain
/
Ramón y Cajal University Hospital/Spain
/
Servicio Galego de Saude/Spain